Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Fish and Richardson
Colorcon
US Department of Justice
Merck
Queensland Health

Generated: April 20, 2019

DrugPatentWatch Database Preview

Mylan Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for MYLAN PHARMS INC, and when can generic versions of MYLAN PHARMS INC drugs launch?

MYLAN PHARMS INC has two hundred and sixty approved drugs.

There are nine US patents protecting MYLAN PHARMS INC drugs. There are twenty-nine tentative approvals on MYLAN PHARMS INC drugs.

There are one hundred and eighty patent family members on MYLAN PHARMS INC drugs in thirty-nine countries and five hundred and thirty-six supplementary protection certificates in fifteen countries.

Summary for Mylan Pharms Inc
International Patents:180
US Patents:9
Tradenames:214
Ingredients:204
NDAs:260

Drugs and US Patents for Mylan Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc ZIPRASIDONE HYDROCHLORIDE ziprasidone hydrochloride CAPSULE;ORAL 202395-004 Oct 10, 2013 DISCN No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc DOXYCYCLINE HYCLATE doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 091052-001 Feb 8, 2012 AB RX No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc DIDANOSINE didanosine CAPSULE, DELAYED REL PELLETS;ORAL 090788-002 Apr 8, 2010 DISCN No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc ESTRADIOL estradiol CREAM;VAGINAL 208788-001 Dec 29, 2017 AB RX No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc SUMATRIPTAN AND NAPROXEN SODIUM naproxen sodium; sumatriptan succinate TABLET;ORAL 090872-001 Sep 4, 2018 AB RX No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc OLANZAPINE olanzapine TABLET;ORAL 076866-006 Apr 23, 2012 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for Mylan Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Pharms Inc LUXIQ betamethasone valerate AEROSOL, FOAM;TOPICAL 020934-001 Feb 28, 1999 6,126,920 ➤ Sign Up
Mylan Pharms Inc LUXIQ betamethasone valerate AEROSOL, FOAM;TOPICAL 020934-001 Feb 28, 1999 7,078,058 ➤ Sign Up
Mylan Pharms Inc OLUX clobetasol propionate AEROSOL, FOAM;TOPICAL 021142-001 May 26, 2000 6,126,920 ➤ Sign Up
Mylan Pharms Inc EXTINA ketoconazole AEROSOL, FOAM;TOPICAL 021738-001 Jun 12, 2007 7,553,835 ➤ Sign Up
Mylan Pharms Inc DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 5,916,893 ➤ Sign Up
Mylan Pharms Inc DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 5,840,763 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for MYLAN PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Foam 2% ➤ Subscribe 2009-07-30
➤ Subscribe Topical Foam 0.05% ➤ Subscribe 2005-06-27
➤ Subscribe Foam 0.12% ➤ Subscribe 2007-08-10

Supplementary Protection Certificates for Mylan Pharms Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0502314 23/1999 Austria ➤ Sign Up PRODUCT NAME: TELMISARTAN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; NAT. REGISTRATION NO/DATE: EU/1/98/089/001-010 19981211; FIRST REGISTRATION: BE K (1998) 4288-DE 19981211
0328535 96C0021 Belgium ➤ Sign Up PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
0812190 SPC/GB05/042 United Kingdom ➤ Sign Up PRODUCT NAME: MESYLATE, ESYLATE OR SULFATE SALTS OF N-PROPARGYL-1(R)-AMINOINDAN (RASAGILINE); REGISTERED: UK EU/1/04/304/001 20050221; UK EU/1/04/304/002 20050221; UK EU/1/04/304/003 20050221; UK EU/1/04/304/004 20050221; UK EU/1/04/304/005 20050221; UK EU/1/04/304/006 20050221; UK EU/1/04/304/007 20050221
1412357 PA2008013 Lithuania ➤ Sign Up PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716
1663240 93382 Luxembourg ➤ Sign Up PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, TEL QU'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, INCLUANT LE SEL CHLORHYDRATE DE RILPIVIRINE ET TENOFOVIR ALAFENAMIDE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE DE TENOFOVIR ALAFENAMIDE; AUTHORISATION NUMBER AND DATE: EU/1/16/1112 ODEFSEY - EMTRICITABINE
1280520 122015000021 Germany ➤ Sign Up PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Deloitte
Citi
Julphar
Cantor Fitzgerald
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.